These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 39050747)

  • 21. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.
    Hu Y; Du Y; Qiu Z; Zhu C; Wang J; Liang T; Liu T; Da M
    Front Pharmacol; 2024; 15():1399998. PubMed ID: 39108741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 24. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.
    Zhang Y; Zhou C; Liu Y; Hao Y; Wang J; Song B; Yu J
    Front Pharmacol; 2024; 15():1472648. PubMed ID: 39376606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
    Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
    Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
    [No Abstract]   [Full Text] [Related]  

  • 28. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax.
    Yang Y; Shu Y; Chen G; Yin Y; Li F; Li J
    PLoS One; 2022; 17(12):e0278725. PubMed ID: 36477747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system.
    Wu L; Xu M; Li X; Aierken D; Yu J; Qin T
    Front Pharmacol; 2024; 15():1418469. PubMed ID: 39263575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety evaluation of ceftazidime/avibactam based on FAERS database.
    Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
    Infection; 2024 Jun; ():. PubMed ID: 38842750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database.
    He B; Zheng W
    Heliyon; 2024 Oct; 10(19):e38450. PubMed ID: 39391518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib.
    Zhang X; Ren X; Zhu T; Zheng W; Shen C; Lu C
    Front Pharmacol; 2024; 15():1407709. PubMed ID: 39114350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database.
    Li S; Huang R; Meng Y; Liu Y; Qian J; Zou J; Yang J
    Front Pharmacol; 2024; 15():1420126. PubMed ID: 39161895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study.
    Yuan T; Li F; Hou Y; Guo H
    Front Pharmacol; 2023; 14():1266890. PubMed ID: 38074150
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.
    Kawaguchi N; Koshimichi H; Ishibashi T; Wajima T
    Clin Drug Investig; 2018 Nov; 38(11):1053-1060. PubMed ID: 30203386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
    Shu Y; He X; Liu Y; Wu P; Zhang Q
    Clin Epidemiol; 2022; 14():789-802. PubMed ID: 35789689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023.
    Lin J; Chen X; Luo M; Zhuo Q; Zhang H; Chen N; Zhuo Y; Han Y
    Front Pharmacol; 2024; 15():1420478. PubMed ID: 39050749
    [No Abstract]   [Full Text] [Related]  

  • 38. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
    Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
    J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
    Wen H; Lu C; Zhang M; Qi X
    Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system.
    Li L; Xu Q; Liu Y; Pang L; Cui Z; Lu Y
    Front Pharmacol; 2024; 15():1403988. PubMed ID: 39114358
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.